candesartan has been researched along with Genetic Predisposition in 6 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| "347 migraine patients aged 18-68 (155 migraine without aura (MoA), 187 migraine with aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years of age were included in the study." | 1.35 | Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. ( Bovim, G; Gladwin, AJ; Owen, K; Schrader, H; Stovner, LJ; Tronvik, E; White, LR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taniguchi, Y | 1 |
| Takahashi, N | 1 |
| Fukui, A | 1 |
| Nagano-Torigoe, Y | 1 |
| Thuc, LC | 1 |
| Teshima, Y | 1 |
| Shinohara, T | 1 |
| Wakisaka, O | 1 |
| Ooie, T | 1 |
| Murozono, Y | 1 |
| Yufu, K | 1 |
| Nakagawa, M | 1 |
| Hara, M | 1 |
| Yoshimatsu, H | 1 |
| Saikawa, T | 1 |
| Turner, ST | 1 |
| Bailey, KR | 1 |
| Schwartz, GL | 1 |
| Chapman, AB | 1 |
| Chai, HS | 1 |
| Boerwinkle, E | 1 |
| Schunkert, H | 1 |
| Skov, K | 1 |
| Eiskjaer, H | 1 |
| Hansen, HE | 1 |
| Madsen, JK | 1 |
| Kvist, S | 1 |
| Mulvany, MJ | 1 |
| Nakamura, T | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Tronvik, E | 1 |
| Stovner, LJ | 1 |
| Bovim, G | 1 |
| White, LR | 1 |
| Gladwin, AJ | 1 |
| Owen, K | 1 |
| Schrader, H | 1 |
2 trials available for candesartan and Genetic Predisposition
| Article | Year |
|---|---|
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Black or African | 2012 |
Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 2007 |
4 other studies available for candesartan and Genetic Predisposition
| Article | Year |
|---|---|
Candesartan restored cardiac Hsp72 expression and tolerance against reperfusion injury in hereditary insulin-resistant rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Benzimidazoles; | 2011 |
A dream yet to become true.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Genetic Predis | 2007 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |
Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2008 |